Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kura Oncology (KURA) Share-based Compensation (2023 - 2026)

Kura Oncology has reported Share-based Compensation over the past 4 years, most recently at $8.4 million for Q1 2026.

  • Quarterly Share-based Compensation rose 7.32% to $8.4 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $37.7 million through Mar 2026, up 13.41% year-over-year, with the annual reading at $37.1 million for FY2025, 9.47% up from the prior year.
  • Share-based Compensation was $8.4 million for Q1 2026 at Kura Oncology, down from $11.4 million in the prior quarter.
  • Over five years, Share-based Compensation peaked at $11.4 million in Q4 2025 and troughed at $6.8 million in Q1 2023.
  • The 4-year median for Share-based Compensation is $8.3 million (2024), against an average of $8.3 million.
  • The largest YoY upside for Share-based Compensation was 31.73% in 2025 against a maximum downside of 17.57% in 2025.
  • A 4-year view of Share-based Compensation shows it stood at $7.2 million in 2023, then grew by 20.43% to $8.6 million in 2024, then surged by 31.53% to $11.4 million in 2025, then dropped by 25.86% to $8.4 million in 2026.
  • Per Business Quant, the three most recent readings for KURA's Share-based Compensation are $8.4 million (Q1 2026), $11.4 million (Q4 2025), and $11.0 million (Q3 2025).